FDA Picks Eli Lilly, Regeneron for Fast-Track Plant Review Program
The FDA selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck Pilot Program to speed manufacturing facility reviews.
The FDA just handed Eli Lilly and Regeneron a serious competitive edge. Both drugmakers are among the first seven companies tapped for the agency's brand-new PreCheck Pilot Program — an initiative designed to accelerate the review of new manufacturing facilities, CNBC has learned.
This is a big deal for investors watching pharma supply-chain plays. Getting a manufacturing site approved faster means these companies can scale production quicker, respond to demand spikes sooner, and reduce the bottleneck risk that's haunted the drug industry since COVID exposed how fragile those pipelines really are.
Read more Boeing, Lockheed, Oracle Back Trump's Freedom 250 Celebration →
For traders, the names matter here. Lilly is already in hyper-growth mode riding GLP-1 demand for Mounjaro and Zepbound. Any regulatory tailwind that clears the path for faster capacity expansion is fuel on that fire. Regeneron, meanwhile, has its own pipeline ambitions that depend on getting manufacturing infrastructure in place at speed.
The PreCheck Pilot Program signals a broader shift in how the FDA is thinking about domestic drug manufacturing — a priority that's gotten louder as geopolitical tensions and tariff threats put foreign production under scrutiny. Being early into a program like this isn't just operationally smart; it's a signal that these companies have the compliance track record to earn that fast lane.
Watch how the other five selected companies get named in coming days — that list could surface under-the-radar names with serious manufacturing buildout stories. Continue reading at US Top News and Analysis.
